Please assess the completion status of the following clinical trial:

Trial Title: Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women between the ages of 18 and 60 years old, inclusive, at the time of screening;~* Females of non-child bearing potential must be ≥1 year post-menopausal (confirmed by a serum follicle-stimulating hormone (FSH) levels ≥ 40 IU/mL) or documented as being surgically sterile. Females of child bearing potential must agree to use two methods of contraception;~* Male subjects must be willing to use clinically acceptable method of contraception during the entire study;~* Body mass index between 18.5 and 26.9 kg/m2, inclusive, at screening;~* Diagnosed with Type 1 diabetes for greater than 2 years, based on clinical history or as defined by the current American Diabetes Association (ADA) criteria;~* HbA1c ≥6.0 % but \<9.0 % at screening;~* Fasting C-peptide \<0.2 ng/mL;~* Current use of insulin pump and willing to use continuous glucose monitoring (CGM) system (e.g. DexCom) throughout the entire study;~* ALT and/or AST within \<1.5x ULN at screening;~* Serum amylase and lipase within normal limits at screening;~* Able to provide written informed consent approved by an Institutional Review Board (IRB).~Exclusion Criteria:~* History or evidence of clinically-significant disorder or condition that, in the opinion of the Investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion;~* Significant organ system dysfunction (e.g., clinically significant pulmonary or cardiovascular disease, anemia \[Hemoglobin \<10.0 g/dL\], and renal dysfunction \[eGFR \<90 ml/1.73M2/min\]);~* Any severe symptomatic hypoglycemic event associated with a seizure or requiring help from other people or medical facility in the past 6 months;~* Current or recent (within 1 month of screening) use of diabetes medications other than insulin;~* Use of steroids and/or other prescribed or over-the-counter medications that are known to affect the outcome measures in this study or known to influence glucose metabolism;~* Smokes tobacco;~* Known sensitivity to mammalian-derived drug preparations, recombinant protein-based drugs or to humanized or human antibodies;~* History of illegal drug use or alcohol abuse within the last 6 months or a positive drug urine test result at screening;~* History of pancreatitis, pancreatic neuroendocrine tumors or multiple endocrine neoplasia;~* History of pheochromocytoma, or family history of familial pheochromocytoma;~* Known or suspected susceptibility to infectious disease (eg, taking immunosuppressive agents or has a documented inherited or acquired immunodeficiency);~* Positive for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HbsAg), or hepatitis C antibodies (HepC Ab);~* Participation in an investigational drug or device trial within 30 days of screening or within 5 times the half-life of the investigational agent in the other clinical study, if known, whichever period is longer;~* Blood donor or blood loss \>500 mL within 30 days of Day 1;~* Women who are pregnant or lactating/breastfeeding;~* Regular exercise \>120 min/week within 14 days of Day 1;~* Unable or unwilling to follow the study protocol or who are non-compliant with screening appointments or study visits;~* Family history of multiple endocrine neoplasia.~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- REMD-477 Treatment A (Type: EXPERIMENTAL): Administered as a single SC dose in subjects with Type 1 Diabetes
- Matching placebo (Type: PLACEBO_COMPARATOR): Administered as a single SC dose in subjects with Type 1 Diabetes

Based on this trial design, predict the completion outcome and termination type (if applicable).